Articles by Patrick Daly
Bilal Abid, MD, describes how to approach sequencing pirtobrutinib after CAR-T therapy.
The positive safety profile of this bispecific antibody makes it well-suited for combination with other treatments.
Adam Kittai, MD, of the Icahn School of Medicine, describes three trials on novel therapies for Richter transformation.
Dr. Abid describes when he uses bispecifics versus CAR-T in his practice at the University of Texas Health Science Center.
Dr. Shadman, of the Fred Hutchinson Cancer Center, shares CLL news from the SOHO 2024 Annual Meeting.
COVID-19 infection was strongly correlated with severity, blast cell percentage, and degree of dysplasia in MDS.
IDH1 inhibitor therapy significantly improved survival after HMA failure in patients with higher-risk MDS.
Luspatercept yielded high rates of durable transfusion independence in heavily-pretreated, lower-risk MDS.
Luspatercept yielded greater rates of improvement in cell lineages for patients with transfusion-dependent MDS.
Dr. Rogers debated against Inhye Ahn, MD, on whether therapy with Bruton tyrosine kinase inhibitors can be discontinued.
COMMANDS is the first trial to perform a head-to-head comparison of luspatercept against an erythropoiesis-stimulating agent.
Brentuximab vedotin plus lenalidomide and rituximab combination showed promising efficacy and potential as bridging therapy.
The addition of daratumumab to VRd induction and consolidation induced higher rates of MRD negativity.
A single tocilizumab dose prior to initiation of teclistamab therapy effectively reduced the incidence of CRS.
Treatment with CELMoDs showed promising efficacy but high rates of neutropenia in patients with multiple myeloma.
Cilta-cel improved outcomes versus standard or care in myeloma, with a safety profile consistent with CAR-T therapies.
The past year in CLL care has seen promising new study findings on BTK inhibition and regulatory approvals.
In the FELIX trial, obe-cel, a CAR-T therapy, achieved a 78% response rate and a 97% MRD negativity rate.
Of the 127 patients who received obe-cel infusion, 74% achieved CR/CRi and 95% had MRD negativity.
ATRA-ATO showed improved efficacy versus ATRA with standard chemotherapy in high-risk APL.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.